Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YDZSG
ADC Name	AMT-562
Synonyms	AMT 562; AMT562 Click to Show/Hide
Drug Status	Investigative
Indication	In total 5 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Colorectal cancer [ICD11:2B91] Investigative Gastric cancer [ICD11:2B72] Investigative Non-small cell lung cancer [ICD11:2C25] Investigative Pancreatic cancer [ICD11:2C10] Investigative
	3D MOL	2D MOL
Antibody Name	Ab562		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-3 (ERBB3)		Antigen Info
Payload Name	Exatecan		Payload Info
Therapeutic Target	DNA topoisomerase 1 (TOP1)		Target Info
Linker Name	Mc-Val-Ala-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 71.8	%	Pancreatic cancer PDX model (PDX: PDX-200930)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Squamous cell carcinoma PDX model (PDX: PDX-361318)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Pancreatic cancer PDX model (PDX: PDX-361319)

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.80% (Day 28)	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 mg/kg, day 1) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-200930)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Squamous cell carcinoma PDX model (PDX: PDX-361318)
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 49)	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-361319)

References

Ref 1	AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. Mol Cancer Ther. 2023 Jun 11:MCT-23-0198. doi: 10.1158/1535-7163.MCT-23-0198. Online ahead of print.